Imexpharm Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Dao Tran

Chief Executive Officer (CEO)

₫5.0b

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	11.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	5.1yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Dao Tran (72 yo)

11.5yrs

Permanencia

₫5,032,239,598

Compensación

Ms. Dao Thi Tran has been General Director at Imexpharm Corporation since May 2013 and serves as its Member of Executive Board. Ms. Tran had been Vice Chairwoman of the Board of Directors at Imexpharm Phar...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dao Tran	General Director	11.5yrs	₫5.03b	sin datos
Tuan Ngo	Deputy General Director & Member of Executive Board	9.7yrs	₫2.43b	sin datos
Nhung Huynh	Deputy General Director & Member of Executive Board	no data	₫2.03b	sin datos
Phuong Van Le	Deputy General Director & Member of Executive Board	no data	₫2.99b	sin datos
Le Kim Nguyen	Secretary of the Board of Directors	9.3yrs	₫442.47m	sin datos
Duy Nguyen	Deputy General Director	less than a year	sin datos	sin datos
Thanh Nguyen	Deputy General Director & Member of Executive Board	less than a year	sin datos	sin datos
Hung Hoang	Chief Accountant & Director	less than a year	sin datos	sin datos

5.1yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMP es experimentado (5.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dao Tran	General Director	no data	₫5.03b	sin datos
Hung Hoang	Chief Accountant & Director	less than a year	sin datos	sin datos
Vinh Thi Han	Non-Executive Director	6.6yrs	₫644.00m	sin datos
Hung Truong	Non-Executive Director	4.5yrs	₫644.00m	sin datos
Suyong Chung	Director	1.6yrs	₫284.31m	sin datos

3.0yrs

Permanencia media

50yo

Promedio de edad

Junta con experiencia: La junta directiva de IMP se considera experimentada (3 años de antigüedad promedio).

Imexpharm Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Imexpharm Corporation, Annual General Meeting, Apr 26, 2024

Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of Directors

Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of Directors

No independent directors

Imexpharm Corporation Announces Personnel Change

No independent directors

Recent updates

Third quarter 2024 earnings released: EPS: ₫436 (vs ₫404 in 3Q 2023)

New minor risk - Share price stability

Price target increased by 9.2% to ₫78,485

Second quarter 2024 earnings released: EPS: ₫794 (vs ₫851 in 2Q 2023)

Investor sentiment improves as stock rises 20%

Upcoming dividend of ₫1,000 per share

Imexpharm Corporation Announces Dividend for the Year 2023, Payable on July 23, 2024

First quarter 2024 earnings released

Imexpharm Corporation, Annual General Meeting, Apr 26, 2024

Full year 2023 earnings released: EPS: ₫3,637 (vs ₫2,810 in FY 2022)

Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of Directors

Third quarter 2023 earnings released: EPS: ₫889 (vs ₫817 in 3Q 2022)

Upcoming dividend of ₫1,000 per share at 1.5% yield

Imexpharm Corporation Announces Dividend, Payable on October 20, 2023

Upcoming dividend of ₫1,000 per share at 1.5% yield

Price target increased by 14% to ₫84,000

Second quarter 2023 earnings released

Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of Directors

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: EPS: ₫3,495 (vs ₫2,600 in FY 2021)

Price target decreased to ₫66,600

Investor sentiment improved over the past week

No independent directors

Third quarter 2022 earnings released: EPS: ₫858 (vs ₫413 in 3Q 2021)

Imexpharm Corporation announced that it has received funding from SK Group Ltd.

Second quarter 2022 earnings released: EPS: ₫615 (vs ₫684 in 2Q 2021)

Price target increased to ₫79,000

Imexpharm Corporation Announces Personnel Change

Upcoming dividend of ₫1,500 per share

Imexpharm Corporation Announces Cash Dividend for 2021, Payable on June 24, 2022

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS ₫413 (vs ₫478 in 3Q 2020)

Price target increased to ₫75,300

Second quarter 2021 earnings released: EPS ₫651 (vs ₫1,180 in 2Q 2020)

Upcoming dividend of ₫1,500 per share

First quarter 2021 earnings released: EPS ₫615 (vs ₫564 in 1Q 2020)

Full year 2020 earnings released: EPS ₫2,773 (vs ₫2,225 in FY 2019)

New 90-day high: ₫60,600

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ₫2,773

New 90-day high: ₫58,000

Price target raised to ₫57,910

New 90-day high: ₫56,800

New 90-day high: ₫54,900

New 90-day high: ₫49,550

Third quarter earnings released

New 90-day high - ₫49,500

New 90-day low - ₫39,650

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad